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I. General Introduction 
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A. 
 
Renal and Cardiac Transplantation: overview and current challenges 
The first successful solid-organ transplantation procedure was performed in Boston, 
USA, in 1954. A kidney was transplanted from a healthy donor to his identical twin 
suffering from kidney failure.1 Although attempts at organ transplantation had been 
carried out decades prior to that, they were unsuccessful.2 Since this first-reported 
successful transplantation,1 the field of organ transplantation has witnessed tremendous 
advancements in scope, number of procedures and outcome quality. Today, organ 
transplantation is considered the treatment of choice for end-stage organ failure. In 2002, 
150,000 individuals were living in the US with functioning allografts compared to 62,000 
in 1993.3
 
 
Despite the great strides that were made in the field of organ transplantation, several 
challenges continue to face clinicians, researchers and health care planners alike, as 
well as -very importantly- patients. The 1-year renal and cardiac transplant survival (90-
95% and 87%, respectively) has improved since the dawn of transplantation. 
Nevertheless, the 10-year survival rates fall dramatically to 51-68% and 50%, 
respectively, with modest improvements over the past two decades.4-6 This is In spite of 
lower rates of acute rejection episodes.7 Progressive allograft tissue damage and 
deterioration of graft function is observed in all transplanted organs and is collectively 
and generically called “chronic allograft dysfunction”. Intervention to effectively prevent 
or interrupt this process remains a challenge.8
 
 
Another challenge is that transplant patients are placed on long-term 
immunosuppression. Clearly, Immunosuppressive drug regimens reduced the rate of 
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acute rejection,8 but they have side-effects which could injure the allograft itself9 or 
cause an increased susceptibility to infections or malignancy.10 The ultimate goal of 
immunosuppression or “immuno-intervention” is to achieve immunologic tolerance; 
intervening at an early stage of transplantation, through manipulation of the immune 
response, so that the recipient immune system no longer identifies the allograft as 
foreign.11 However, trials that tested the impact of withdrawal of immunosuppressant 
medication showed deterioration of graft function for the majority of the patients.12, 13
 
  
A multitude of medical conditions and co-morbidities complicate the medical care of 
transplant recipients and pose another major challenge. One study reported that 
approximately 30% of all deaths in renal transplant patients after the first year are due to 
cardiovascular complications.14 Infection and malignancies account for 11% and 10%, 
respectively, of such deaths.14 Diabetes is highly prevalent in transplant patients (20%)15 
and constitutes in itself another risk factor for cardiovascular diseases. Additionally, 
immunosuppressive therapy using calcineurin inhibitors and corticosteroids has been 
associated with higher incidence of diabetes after transplantation. 16
 
 
More than 50 years have passed since the first report of a successful solid-organ 
transplantation procedure. Tremendous advancements have taken place in all different 
aspects of the transplantation process, which in turn made this treatment option a widely 
applied therapy for end-stage organ failure. A host of challenges, however, need to be 
overcome to optimize outcomes and reduce risks of this therapeutic modality. The 
continued research in the field of organ transplantation and cellular and molecular 
biology will hopefully bring us closer to that goal. 
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B. Chronic Allograft Nephropathy (CAN): etiology and mechanisms 
Although the term CAN has been used extensively in the literature to describe any 
pathologic change that affects the renal allograft, the need to identify specific causes of 
CAN and understand the underlying mechanisms of allograft injury has been 
emphasized in recent years17, 18
 
. The identification of such mechanisms is necessary to 
devise appropriate treatments and interventions for the long-term management of renal 
transplant patients.  
Chronic damage and injury to renal allografts is mediated by alloimmune-dependent and 
alloimmune-independent mechanisms19, 20. One of the major alloimmune-dependent 
mechanisms of CAN is chronic rejection17, 18. Chronic rejection manifests as a slowly 
progressive cortical scarring of the allograft. This is mainly an antibody-mediated 
process as evidenced by the widespread C4d deposits (split product of the complement 
system classic pathway, marker of antibody-induced injury21) in the peritubular 
capillaries viewed by immunofluorescence microscopy22, 23.  Human and animal studies 
have shown that donor-specific antibodies were associated with the development of 
CAN24, 25. Chronic, T-cell-mediated, allograft arteriopathy is also observed. This is 
suggested by the disruption of the lamina elastica interna, inflammatory cells in the 
fibrotic intima and proliferation of myofibroblasts in the intima26, 27. It is more likely, 
however, that chronic injury is mediated by an interplay of both the humoral and cellular 
arms of the immune system28. The role of calcineurin inhibitor (CNI) toxicity as a 
contributor to allograft damage has been recognized for several years9, 29
 
. 
The exact mechanisms that cause allograft damage are not clearly understood but they 
all proceed through inflammatory pathways that involve the activation and upregulation 
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of different cytokines and adhesion molecules. For example, a recent animal study 
reported that an interleukin 6 (IL-6) -neutralizing antibody prevented occurrence of 
cyclosporine induced nephrotoxicity30
Other alloimmune-independent risk factors include older donor age
. 
31, 32, younger 
recipient age32, delayed graft function33 and ischemia-reperfusion injury34
 
. 
C. Periodontitis: association with systemic inflammation 
Periodontitis is a chronic inflammation of the tooth-supporting tissues that is caused by 
an interplay between a sub-gingival, predominantly gram–negative, bacterial 
plaque/biofilm and an overt inflammatory response of a susceptible host 35, 36
 
. 
Periodontitis is characterized by progressive loss of the attachment and supporting bone 
of the tooth and, if left untreated, leads to eventual tooth loss. 
The past decade has witnessed an explosion of information regarding a link between 
periodontitis and systemic diseases. Since several epidemiologic studies37, 38 reported a 
significant association between periodontal disease and cardiovascular disease (CVD), 
the volume of research investigating a role for periodontitis in systemic inflammation and 
systemic disease, including stroke39, diabetes mellitus40, pre-term pregnancy41 and end-
stage renal disease42
 
 has been increasing exponentially.   
In a meta-analysis of longitudinal and cross-sectional studies, Bahekar et al43 reported 
that patients with periodontitis had a higher risk for developing CVD with a relative risk of 
1.14 in prospective studies and odds ratio of 1.59  to 2.2 in case-control and cross-
sectional studies. A randomized controlled interventional study44 has shown that 
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intensive periodontal treatment improved endothelial function, a surrogate marker for 
future atherosclerosis45, and reduced serum E-selectin levels at 2 and 6 months. This 
association, however, has not been confirmed in other studies46, 47. Other interventional 
studies are ongoing48
 
 and are expected to provide more information on the causality of 
the link and/or the benefit from periodontal treatment as measured by true endpoints of 
CVD. 
A very interesting area of research in this field is to elucidate the mechanisms that 
explain the association between periodontitis and systemic inflammation and systemic 
diseases. One proposed mechanism is that many systemic diseases (e.g. 
atherosclerosis, diabetes mellitus) are in essence either induced or propagated by an 
inflammatory process49, 50, and periodontal inflammation contributes incrementally to 
systemic inflammatory mediator levels. This would in turn contribute to the worsening or 
acceleration of the existing systemic disease. In support of this hypothesis, human 
studies reported higher serum C-reactive protein (CRP)51, 52,(IL-6)52, tissue plasminogen 
activator (TPA)53, tumor necrosis factor alpha (TNF-α)54, 55 in subjects with periodontal 
disease compared to periodontally-healthy subjects. While several studies reported a 
reduction of systemic cytokine levels after periodontal treatment54, 56, other studies did 
not find significant reductions57, 58
 
.  Thus, further interventional studies with long-term 
follow-up are required to evaluate the benefit of periodontal treatment in modifying 
systemic inflammation and influence on systemic disease experience. 
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II. Periodontitis and Inflammatory Markers in Transplant Recipients 
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A. 
1. General objective:  
Objectives: 
To investigate whether inflammatory periodontal disease in solid-organ transplant 
recipients influences/contributes to systemic inflammatory cytokine levels, which 
might in turn affect the clinical course of the allograft. 
2. Specific objectives: 
Using a population of stable, solid-organ, transplant patients, and an age-
matched systemically-healthy control population, we aimed to: 
a) Investigate the prevalence of periodontal disease in a solid-organ transplant 
population and compare it to the prevalence of periodontal disease in a 
systemically-healthy control population. 
b) Investigate if periodontal disease and different periodontal parameters are 
correlated with systemic interleukin 6 (IL-6) and C-reactive protein (CRP), 
after adjusting for known predictors/determinants of their systemic levels. 
c) Investigate if IL-6 mRNA levels in gingival tissue from diseased sites are 
correlated with systemic levels of IL-6 in solid organ recipients. 
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B. 
The link between periodontal inflammation and systemic health has been the focus of 
much scientific research in the past few years. This was stimulated by a better 
understanding of the role of inflammation in the pathogenesis of periodontitis and certain 
systemic diseases
Introduction: 
49, 59, 60. One proposed pathogenetic mechanism is that excessive 
release of inflammatory cytokines in diseased periodontal tissues contributes to the 
serum cytokine pool, which promotes systemic disease. Evidence supporting this 
hypothesis comes from ex-vivo and clinical studies. Cells within the diseased 
periodontium produce significantly higher levels of IL-6 compared to healthy gingival 
tissues, and periodontal disease has been linked to higher serum IL-6 in several 
studies61, 62. Similarly, serum CRP has been reported to be elevated in patients with 
periodontitis63. Perhaps, the most convincing evidence for a causal association between 
systemic and periodontal inflammation comes from studies showing that treatment of 
periodontitis reduced serum glycated hemoglobin and inflammatory marker levels in 
diabetic64 or healthy subjects44
 
. 
Solid organ transplantation is the definitive therapeutic approach in patients with end-
stage organ disease. Kidney and heart are the most commonly transplanted organs, with 
more than 17,000 kidney and 2,000 heart transplants performed in the United States in 
2008 (http://optn.transplant.hrsa.gov). Despite the high graft survival rates after the first 
year post-transplantation (more than 85%), the 10-year graft survival rates decrease 
dramatically (less than 55%)65. The main effector mechanism for chronic transplant 
deterioration is inflammation which is modulated by alloimmune-dependent and 
alloimmune-independent factors. Examples of alloimmune-dependent factors are human 
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leukocyte antigen (HLA) mismatches, panel reactive antibody (PRA) scores and acute 
rejection. Alloimmune-independent factors include cold ischemic time, 
ischemia/reperfusion injury, smoking, diabetes, and living versus cadaveric donor20, 66. 
Clinically, serum and urine IL-6 levels are indicators of acute rejection episodes67, 68 and 
successful anti-rejection therapy reduces serum IL-669. Similarly, CRP was shown to be 
a predictor of renal allograft survival70
 
. 
Given the importance of IL-6 and CRP in transplant deterioration and the link between 
periodontitis and these systemic inflammatory markers, we explored whether 
periodontitis is a modifier of systemic IL-6 and CRP in solid organ transplant recipients. 
Thus, the goals of this study were: a) to assess the periodontal status of organ 
transplant recipients and compare it to an age-matched healthy group; b) to assess 
serum IL-6 and CRP levels and test a possible association between serum levels and 
gingival IL-6 mRNA expression.  
  
C. 
1. Subject recruitment 
Materials & Methods: 
One hundred and forty-four renal and cardiac transplant recipients were screened during 
routine outpatient visits at Hartford Hospital Transplant Center. Inclusion criteria were: 1) 
clinically stable (measured by serum creatinine levels and cardiac ejection fraction in 
renal and cardiac transplant patients, respectively); 2) at least 1 year post-transplant; 3) 
absence of other systemic conditions that might directly affect systemic inflammatory 
status e.g. rheumatoid or autoimmune diseases; 3) negative history of antibiotic use 
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during the preceding 4 months; and 4) no periodontal treatment within the last year. 
Ninety renal and cardiac transplant patients met these criteria. 
Recruitment strategy of controls included: 1) broadcast email to University of 
Connecticut Health Center (UCHC) employees; 2) Invitation letters mailed to General 
Clinical Research Center and Women’s Health Center patients at UCHC; 3) 
Advertisements in local newspapers. Seventy-two systemically healthy subjects with no 
periodontal treatment within the last year and no history of antibiotic use during the 
preceding 4 months were recruited (36 UCHC employees, 16 invitation letter 
respondents and 20 newspaper advertisement respondents). The study was approved 
by the Institutional Review Boards of UCHC and Hartford Hospital.  
 
2. Data Collection 
Medical information of transplant subjects was extracted from hospital records and 
included age, gender, ethnicity, weight, height, diabetic status, smoking history, number 
of years since transplant, history of rejection episodes, medication regimen/dosages, 
HLA mismatching, PRA score, cadaveric or living donor, related or unrelated donor. A 
detailed health review questionnaire was used in the control group which included 
questions that might identify an undiagnosed systemic condition (e.g. frequency of 
urination, dermatologic lesions). 
 
All subjects received a comprehensive oral examination including opportunistic 
infections, caries, missing teeth, plaque index (PI), bleeding on probing (BOP), probing 
depth (PD), clinical attachment level (CAL) and gingival overgrowth (GO) according to 
Pernu et al71. Advanced periodontitis was defined as at least 2 interproximal sites with 
CAL≥6mm (not on the same tooth) plus 1 interproximal site with PD≥5mm72. 
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3. Blood and Tissue Sampling: 
Fifteen ml of venous blood were drawn from all subjects prior to oral examination.  
Gingival granulation tissue was collected from transplant patients with advanced 
periodontitis (n=19) who received non-surgical periodontal therapy, using a sharp curette 
in the deepest pocket. Gingival tissue samples were snap frozen in liquid nitrogen and 
stored at -80º C. 
 
4. Sample analyses:  
Within 2 hours of blood collection, sera were separated after clotting for 30 minutes at 
4ºC, followed by centrifugation at 3,000 x g for 15 minutes. Aliquots were stored at -80ºC 
until testing. Sera were coded and analyzed in duplicate by ELISA1
 
. The IL-6 and CRP 
assay analytical sensitivities were 2.0 pg/ml and <0.3 mg/L, respectively, and the 
variation in protein values within runs was <1% for both assays. 
Total RNA was extracted from gingival samples2 and quantitative real-time PCR3 was 
performed using commercially available primers and probes4
                                               
 
 
1 Diagnostic Products, Los Angeles, CA. 
 for IL-6. The PCR product 
2 TriZOL, Invitrogen, Carlsbad, CA. 
3 TaqMan Universal PCR Master Mix, Applied Biosystems. 
4 Applied Biosystems, Bedford, MA. 
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was measured in 40 consecutive cycles during each reaction using appropriate 
software5. IL-6 cDNA was normalized using 3 housekeeping genes (GAPDH, actin and 
β2
 
M) in each sample. Nuclease-free water was used as a negative control in each 
reaction. 
5. Statistical Analyses 
Means and medians of continuous periodontal variables and percentage of sites with 
PD≥5mm or CAL≥4mm were calculated for each subject and group. Considering the 
frequency distribution of the values above the threshold of detection, undetectable 
serum IL-6 values were recorded as 0.5 pg/ml. Natural logarithm transformation was 
applied to non-normally distributed variables. Continuous and dichotomous variables 
were compared among groups using a two-sample student t-test or χ2
 
 test, respectively. 
Multivariate linear regression analysis determined predictors of serum IL-6 and CRP. 
Our transplant group sample size permits detection of an effect size of 0.18 at a p=0.05, 
in a multivariate analysis with 6 predictors and β≤0.2. Pearson correlation tested 
associations between serum IL-6, CRP and continuous periodontal variables. Partial 
correlations test was used to test the association between serum IL-6 and periodontal 
tissue IL-6 mRNA levels while controlling for diabetes. p≤0.05 was considered 
statistically significant. 
                                               
 
 
5 iCycler iQ PCR detection system software, Bio-Rad. 
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D. 
1. Population characteristics and periodontal findings 
Results 
Population demographics, periodontal and serum findings in transplant and control 
groups appear in Table 1 (page 40) and Table 2 (page 42). Controls had slightly more 
females, lower body mass index (BMI) and lower percentage of diabetics compared to 
the transplant group. Mean PD, percentage of sites with PD≥5mm, percentage of sites 
with CAL≥4mm and number of missing teeth were higher in the transplant group 
compared to control. Twenty-one percent of the transplant subjects had advanced 
chronic periodontitis compared to 15% of the controls, but the difference was not 
statistically significant (p=0.34). Six and a half percent of the transplant group had mild 
localized gingival overgrowth (score 1), compared to 0% in the control group. 
 
2. IL-6, CRP and periodontal status 
The transplant group had higher mean serum IL-6 and CRP levels compared to the 
control group (Table 1, page 40). Serum IL-6 and CRP levels were positively correlated 
with each other, in transplant (r=0.46, p<0.001) and control groups (r=0.35, p=0.003). In 
the transplant group, there was no significant correlation between serum IL-6 or CRP 
levels and any of the periodontal indices, but the number of missing teeth showed a 
positive correlation with serum IL-6 (r=0.29, p=0.006). 
 
Despite the lack of correlation between serum IL-6 and periodontal parameters, 
transplant patients with advanced periodontitis had a significantly higher serum IL-6 
compared to non-periodontitis transplant subjects (6.0±4.2 pg/ml vs 4.7±4.4 pg/ml, 
p=0.04) and there was a trend towards higher serum CRP in this group as well (1.36 
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±1.89 mg/L vs 0.77±1.54 mg/L, p=0.12). Serum protein and gingival mRNA IL-6 levels 
were positively correlated in transplant subjects with advanced periodontitis, after 
adjusting for diabetes, but correlations were not statistically significant for any of the 
housekeeping genes (GAPDH: r=0.32, p=0.17; β2
 
M: r=0.28, p=0.23; actin: r=0.27, 
p=0.26).  
In the control group, serum IL-6 levels were positively correlated with mean PD (r=0.37, 
p=0.002), percentage of sites with PD≥5mm (r=0.33, p=0.006) and mean BOP (r=0.38, 
p=0.001). Similarly in this group, serum CRP levels were positively correlated with mean 
PD (r=0.30, p=0.01) and CAL (r=0.29, p=0.01), whereas the correlation with the 
percentage of sites with PD≥5mm approached statistical significance (r=0.23, p=0.06). 
Differences in serum markers between advanced periodontitis and non-periodontitis 
control subjects did not reach statistical significance (3.7±1.3 pg/ml vs 2.9±1.6 pg/ml, 
p=0.06, and 0.38±0.42 vs 0.27±0.38, p=0.38, for IL-6 and CRP, respectively).  
 
3. Predictors of serum inflammatory markers 
In the transplant group, independent predictors of serum markers that were tested in the 
multivariate model were age, gender, diabetes (yes/no), smoking status (current/former 
vs. never smoker), BMI, years since transplant, immunosuppressant dose (prednisone, 
dichotomized at the 75th
Table 3
 percentile), cyclosporine (yes/no), tacrolimus (yes/no), history of 
rejection (yes/no), living donor (yes/no), HLA mismatches, PRA score, advanced 
periodontitis, as well as all continuous periodontal variables. Variables with p value >0.2 
were excluded from the model. The final model is shown in  (page 43) and Table 
4 (page 44). Significant predictors of higher serum IL-6 in this group were older age, 
diabetes, higher BMI, and cadaveric donor, whereas the number of years post transplant 
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approached statistical significance. In the control group advanced periodontitis, higher 
BOP and greater percentage of sites with PD≥5mm were significant predictors of higher 
serum IL-6, whereas BMI approached statistical significance (Table 3, page 43). With 
respect to serum CRP levels, diabetes and higher BMI were significant predictors of 
higher CRP in the transplant whereas in the control group, only higher BMI was a 
significant predictor (Table 4, page 44). 
 
E. 
The prevalence of advanced chronic periodontitis in our transplant population was higher 
than the control group, but the difference was not statistically significant. The statistically 
significant differences we observed in certain continuous periodontal variables are 
clinically small and not unexpected considering that the transplant group had greater 
numbers of diabetics and former or current smokers, both of which are risk factors for 
periodontitis 
Discussion 
73, 74. Other studies, reported higher 75, 76, similar 77 or lower 78
In this study, periodontitis was defined using the AAP/CDC criteria for severe 
periodontitis 
 prevalence of  
periodontitis in transplant subjects compared to controls. However, differences in 
periodontitis case definitions prohibit a direct comparison between studies.  
72. This definition was chosen for several reasons: First, the definition is 
very stringent in its severe disease category, so that true disease can be detected 
outside the margin of measurement error. Second, this classification enables the 
identification of a population subset with a more pronounced and more readily 
identifiable systemic impact of periodontal inflammation 51, 56. Third, the adoption of this 
definition by our study and, hopefully, future population-based studies will make the 
interpretation and comparison of data more feasible. 
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The transplanted organ constitutes a constant challenge to the host immune system. 
Chronic low-grade activation of inflammatory cells results in a cascade of events leading 
to elevated systemic inflammatory mediator levels 79, 80. This explains our finding of 
elevated levels in circulating IL-6 and CRP in transplant subjects compared to healthy 
controls, as shown in earlier reports by our group and others 81, 82
 
 
Interestingly, studies have reported that the exact sources of serum IL-6 are unclear and 
may originate in tissues other than the transplanted organ 83, 84. While advanced 
periodontitis was a significant predictor of serum IL-6 in the control group, it was not a 
significant predictor in the transplant group (F=0.06, p=0.8). Significant predictors of 
higher IL-6 were older age, diabetes, higher BMI and a cadaveric donor, consistent with 
other reports in the literature 85-88
 
.  
The lack of significance in the multivariate analysis between periodontal parameters and 
inflammatory markers in transplant subjects, which contradicts some of our preliminary 
findings 82, could be due to several reasons. A possible explanation is a true lack of 
association, given the strong “inflammatory” confounding by diabetes and the constant 
allograft-mediated antigenic stimulation in transplant subjects. Another reason could be 
that periodontally-driven inflammation is dampened by immunosuppressive therapy, 
which is supported by the finding that transplant patients experience limited progression 
of periodontitis after initiation of immunosuppression 77
 
.   
The positive correlation between serum and gingival IL-6 in transplant patients, 
consistent with our preliminary findings 82, is noteworthy. Although only having a trend 
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for statistical significance, this moderate size correlation, considering the small sample 
size and possible effects of immunosuppressive treatment on the periodontium, 
suggests a possible contribution of periodontal tissue IL-6 to circulating IL-6. 
Nevertheless, clinical periodontal indices were not predictive of serum IL-6 in the 
transplant population. These seemingly conflicting findings could be reconciled by 
acknowledging that periodontitis levels were relatively low in our transplant population, 
which might have prohibited finding a significant association with serum IL-6 levels. 
Additionally, gingival mRNA levels were only quantified in the deepest pockets of a 
transplant subset with advanced periodontitis whereas clinical periodontal indices were 
assessed in all patients. 
 
The cross sectional nature of this study prevents the assessment of a cause and effect 
relationship between periodontitis and systemic inflammation. Future research should 
aim at longitudinal evaluation of periodontal indices and their correlation with systemic 
markers of inflammation, as well as the influence of periodontal treatment on local and 
systemic markers of inflammation in this population.
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III. Periodontal Disease, Renal Function and Chronic Allograft 
Nephropathy 
20 
 
 
A. 
1. General objectives: 
Objectives: 
To investigate if clinical and/or histological renal allograft deterioration is associated with 
periodontal disease severity, and to determine whether the choice of clinical 
determinants of periodontal disease can affect statistical outcomes. 
2. Specific objectives: 
Using a population of stable renal transplant patients: 
a) To investigate if deterioration in glomerular filtration rates (GFR) is 
associated with periodontal disease severity or various periodontal 
parameters. 
b) To investigate if biopsy-proven Chronic Allograft Nephropathy (CAN) is 
associated with prevalence of periodontitis, or clinical indices of severity of 
periodontitis. 
c) To investigate whether different periodontitis case definitions modify the 
resulting associations with GFR changes or biopsy-proven CAN. 
21 
 
 
B. 
More than 16,500 kidney transplants were performed during 2008 across the US 
(http://optn.transplant.hrsa.gov). Despite greatly improved 1-year survival rates of renal 
transplants from living and deceased donors (90 and 95%, respectively), the 10-year 
graft survival rates fall dramatically to 46 and 58%, respectively
Introduction: 
89. In renal transplants, 
50–80% of these late failures are attributable to chronic allograft nephropathy (CAN) 89, 90 
which is considered the most important cause of renal graft failure after the first year of 
transplantation90, 91. CAN is a descriptive term for a number of histologic lesions in renal 
transplants characterized by progressive interstitial fibrosis, glomerulopathy, mesangial 
matrix increase, vascular fibrous intimal thickening and arteriolar hyaline thickening20
 
. 
Clinically, CAN presents as progressive deterioration in renal function, proteinuria, and 
occasionally, de novo or secondary hypertension. 
Several alloimmune-dependent and alloimmune-independent factors are believed to 
influence the development of these histologic changes. Examples of alloimmune factors 
include acute rejection episodes, subclinical rejection, HLA mismatching and 
allosensitization. Alloimmune-independent factors include graft ischemia, donor age, 
cytomegalovirus infection, brain death, calcineurin inhibitors, recipient morbidity, 
smoking, diabetes mellitus, age, obesity and hyperlipidemia20. These different 
contributing factors are thought to result in transplant endothelial cell injury and 
activation, which is considered to be a key event in the pathogenesis of CAN. 
Endothelial cell activation triggers a cascade of complex and interdependent events. The 
activated endothelium secretes an array of inflammatory cytokines (interleukin 6 (IL-6), 
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interleukin 1 (IL-1), tumor necrosis factor alpha (TNF-α)) leading to progressive 
stimulation of other inflammatory cells (e.g. macrophages, T-lymphocytes).  This in turn 
triggers upregulation of adhesion molecules such as ICAM’s, selectins and MHC 
molecules. Thus, leukocyte infiltration is promoted and further cytokine release takes 
place from activated inflammatory cells leading to phenotypic switching of key effector 
cells (glomerular mesangial cells, fibroblasts, smooth muscle cells). These series of 
processes culminate in the accumulation of extracellular matrix proteins in the 
interstitium and intima of the vascular endothelium. A vicious circle of sustained 
inflammatory reaction from the host’s immune system to the allograft is established, and 
leads to progressive graft destruction and loss of function. Interestingly, a heightened 
pre-transplant or post-transplant systemic inflammation, as measured by a multitude of 
serum cytokines (e.g. C-reactive protein (CRP), vascular adhesion molecule-1, 
interleukin 12) has been associated with worse renal allograft outcomes including acute 
and chronic rejection70, 92-95
 
. 
An oral inflammatory disease that received much attention recently due to a possible link 
with systemic inflammation is chronic periodontitis. Chronic periodontitis and consequent 
destruction of periodontal tissues is believed to be caused by an interplay between a 
sub-gingival, predominantly Gram–negative, bacterial plaque/biofilm and an overt 
inflammatory response of a susceptible host35, 36. Many studies have attempted to 
dissect the determinants of host susceptibility to periodontal disease96-99. For example, 
epidemiological studies showed that the variability in the level of plaque control within a 
population is not always commensurate with disease prevalence100, 101. Moreover, 
molecular analysis of microbial flora revealed a weak positive predictive value for the 
presence or absence of specific periodontal pathogens and disease activity100-102. 
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Several studies have also shown a hyper-active phagocytic cell phenotype in chronic 
periodontitis patients103, 104, in which excessive production of inflammatory cytokines, 
proteases and generation of higher levels of reactive oxygen radicals result in  
destruction, as opposed to a protection103, 104
 
. Cumulatively, this evidence indicates that 
host susceptibility to periodontitis is related to a hyper-inflammatory phenotype leading 
to an exaggerated inflammatory response to microbial challenge and subsequent 
untoward destruction of the attachment apparatus.  
There is accumulating evidence that links periodontal disease to various systemic 
diseases and conditions, including diabetes mellitus40, 105, cardiovascular disease43 and 
poor pregnancy outomes106-108. Moreover, higher systemic inflammatory cytokine levels, 
such as CRP, IL-6 and E-selectin, have been associated with periodontal disease44, 51, 57, 
62, 63 and significant reductions were seen after periodontal treatment44, 54, 109. These 
findings, however, were not confirmed in other studies57, 110-112. Interestingly, a recent 
study113 reported that the criteria used to diagnose/define a case of periodontitis has a 
significant impact on the resulting associations between periodontitis and pre-term, low-
birth weight pregnancy. The significance of the definition applied to diagnose a case of 
periodontitis is also apparent when large epidemiologic studies are compared72
 
, since 
some of the observed trends in disease prevalence and related associations are merely 
due to different disease thresholds being applied. 
Given the evidence that links periodontitis to a hyper-reactive inflammatory phenotype103, 
104 and higher systemic inflammatory cytokine levels9, 51, 63, we hypothesized that 
periodontal disease could serve as a marker to identify subjects with a systemic hyper-
inflammatory phenotype that may consequently be at greater risk for long-term renal 
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allograft deterioration. This would have several implications. For example, a history of 
periodontitis may identify a population in need of more strict criteria in HLA-matching 
before transplantation. This could also necessitate closer monitoring of periodontitis-
susceptible individuals after renal transplantation for signs of CAN and additional graft 
biopsies might be indicated. Finally, in as much as chronic periodontitis can affect 
systemic inflammatory cytokine levels, this oral infection could also be causally linked to 
CAN, although the cross-sectional nature of our study cannot test this hypothesis. The 
aim of this analysis is to investigate the association between the periodontal status of a 
cohort of renal transplant patients and renal allograft function and biopsy-proven CAN. 
Additionally, considering the reported impact of periodontal disease definition on the 
observed associations with systemic disease, we investigated the impact of applying 
three different periodontitis case definitions on the observed associations. 
 
C. 
1.  Subject recruitment 
Materials and methods: 
For the purposes of this analysis, a subset of the population described in chapter 2 was 
included. This subset was defined by the following criteria: 1) clinically-stable renal 
transplant subjects; 2) at least 1 year post-transplant; 3) absence of other systemic 
conditions that might directly impact the systemic inflammatory status (e.g., rheumatoid 
or autoimmune diseases); 3) negative history of antibiotic use during the preceding 4 
months; and 4) no periodontal treatment within the last year; 5) availability of data on the 
highest and lowest serum creatinine tests on record, with these tests being at least 6 
months apart and at least 6 months after the transplant. Fifty-eight renal transplant 
patients who met these criteria were included. 
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2. Data Collection  
Medical information of the subjects was extracted from medical records. A standardized 
extraction form was used. The extracted data included: patient demographics (age, 
gender, ethnicity, weight, and height), co-existing systemic conditions, e.g. diabetes 
(yes/no), hypertension (yes/no), smoking status (current, former and never smoker), 
number of years since transplant, history of rejection episodes, medication regimen and 
dosages, graft survival risk factors (e.g. human leukocyte antigen (HLA) mismatching, 
panel reactive antibody (PRA) score, cadaveric or living donor (related or unrelated), 
delayed graft function, cold ischemic time, dialysis before transplant, cytomegalovirus 
infection), serum creatinine lab results and allograft biopsy reports if available. 
 
Using the highest and lowest serum creatinine values for each subject, GFR values were 
estimated using the 4-variable simplified MDRD formula 114 (estimated GFR=186 x 
Serum Creatinine -1.154 x Age -0.203 x [1.210 if Black] x [0.742 if Female]). Subjects were 
divided into two groups based on whether a deterioration or improvement of GFR 
occurred over time (subjects with no change were included in the latter group). In 
addition, using the Banff 1997 classification27
Table 5
, the subjects were classified according to 
the degree of chronic allograft nephropathy as determined in available biopsy reports. 
The criteria for the different categories of this classification are shown in  (page 
45). 
 
Subjects received a comprehensive oral examination. The following parameters were 
evaluated and recorded: soft tissue lesions, opportunistic infections commonly 
associated with immunosuppression, caries, missing teeth (excluding third molars), 
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plaque score (PS), bleeding on probing (BOP), probing depth (PD), clinical attachment 
level (CAL) and gingival overgrowth (GO) based on the gingival overgrowth index by 
Pernu et al71. Chronic periodontitis was defined using 3 different definitions: the first 
definition (DEF1) was 2 or more inter-proximal sites with PD≥5mm or CAL≥4mm (not on 
the same tooth). The second definition of chronic periodontitis (DEF2) was 6 or more 
inter-proximal sites with PD≥5 or CAL ≥ 4. The third definition of chronic periodontitis 
(DEF3) was 2 or more inter-proximal sites in each quadrant with a PD≥5 or CAL ≥ 4. 
These definitions were chosen because DEF1 comprises of the moderate and severe 
periodontitis categories of the AAP/CDC periodontitis case definition72
 
, and DEF2 and 
DEF3 are arbitrary definitions that were devised to represent an escalating extent of 
periodontal destruction compared to DEF1. 
3. Blood sampling and analyses: 
Fifteen ml of venous blood were withdrawn from all subjects prior to oral examinations. 
Serum IL-6 and CRP were measured using enzyme-linked immunosorbent assay. 
Techniques were described in detail in chapter I (page 12). 
 
4.  Statistical analyses:  
A natural log transformation was applied to non-normally distributed variables. Means 
and medians were calculated for continuous variables. Student t-test was used to test for 
differences between the groups (GFR deterioration vs. improvement). A multivariate, 
repeated measures, linear regression analysis was applied to determine significant 
predictors of the within-subject change in GFR values over time. Student t-test was used 
27 
 
to test for differences of the periodontal variables between the different Banff CAN score 
groups. A p value ≤0.05 was considered statistically significant. 
 
D. 
The population demographic and medical data are reported in 
Results: 
Table 6 (page 46). 
Diabetic patients comprised 52% of the subjects and 53% were former or current 
smokers. The median number of years post-transplant was more than 7 years. The 
mean time between the two serum creatinine tests was 44.7±43 months with a range of 
(6-200) months. 60% of the subjects had a deterioration of estimated GFR levels with a 
median value of GFR deterioration of 50 ml/min/1.73 m2 Table 7 ( , page 47). Serum IL-6 
and CRP were not statistically significantly different among the GFR deterioration vs. 
improvement/stable groups but there was a trend for higher serum IL-6 and CRP in the 
GFR improvement (Table 8, page 48). 
 
Periodontal parameters in the GFR improvement vs. deterioration groups are reported in 
Table 9 (page 49). There were no statistically significant differences in mean PD, mean 
CAL, percentage of sites with BOP, plaque score, percentage of sites with PD≥5mm, 
percentage of sites with CAL≥4mm or the number of missing teeth among the two 
groups. The prevalence rates of chronic periodontitis in the GFR improvement vs. 
deterioration groups according to the 3 different definitions used are described in Table 
10 (page 50). There were no significant differences in the prevalence of periodontitis 
between the two groups when DEF 1 and DEF3 were used. However, using DEF2, 
chronic periodontitis was more prevalent in the GFR deterioration group and the 
difference was statistically significant (Fisher’s exact test, p=0.02) (Table 10, page 50). 
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The serum IL-6 and CRP levels in subjects with and without periodontitis according to 
the 3 different definitions are shown in Table 11 (page 51). No statistically significant 
differences were observed.  
 
A multivariate, repeated measures, linear regression analysis was conducted to 
determine significant predictors of the GFR change over time. The variables included 
were body-mass index (BMI), diabetes status (yes/no), smoking history (yes/no), living 
or cadaveric donor, hypertension, dialysis before transplantation, cold ischemic time, 
delayed graft function, acute rejection episodes (yes/no), panel reactive antibody score, 
HLA mismatch (less than 3 vs. 3 mismatches or more), cytomegalovirus infection 
(yes/no), prednisone use (yes/no), cyclosporine use (yes/no), serum IL-6 and serum 
CRP. Continuous periodontal parameters such as mean PD, mean CAL, percentage of 
sites with BOP, percentage of sites with PD≥5mm, percentage of sites with CAL≥4mm 
and the number of missing teeth were included individually in the model (i.e. they were 
not tested simultaneously). Chronic periodontitis, as defined by each definition was 
included in the model individually. Variables that returned a p value >0.2 were excluded 
from the final model. Accordingly, the following variables were excluded from the final 
analysis:  BMI, diabetes status (yes/no), smoking history (yes/no), dialysis before 
transplantation, cold ischemic time, delayed graft function, panel reactive antibody score, 
HLA mismatch (less than 3 vs. 3 mismatches or more, cytomegalovirus infection, 
prednisone use (yes/no), cyclosporine use (yes/no), serum IL-6 and serum CRP. The 
model which includes the significant medical predictors is shown in Table 12 (page 52). 
The direction of change predicted by each of these variables can be deduced by 
examining the estimated means of GFR within the categories of each variable, shown in 
Table 13 (page 53). GFR change over time (the dependent variable) was statistically 
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significant (F=6.12, p=0.02; this represents the impact of time between the two serum 
creatinine measurements on GFR levels within the same subject). History of acute 
rejection, having a living donor, and being hypertensive statistically significantly 
predicted deterioration of renal allograft function. When the continuous periodontal 
variables were introduced individually into the model, the percentage of sites with BOP, 
mean PD and the percentage of sites with PD≥5mm showed a trend towards statistical 
significance in predicting GFR change (Table 14, page 54). To determine the direction of 
change predicted by each of these variables (percentage of sites with BOP, mean PD 
and the percentage of sites with PD≥5mm), the variables were re-coded into a 
trichotomy with cutoff points at the 25th and 75th
Table 15
 percentiles. The estimated means of 
GFR within the categories of each of these variables are shown in  (page 55). 
Subjects with higher percentage of sites with BOP or PD≥5mm, or a higher mean PD, 
had a trend for greater GFR deterioration. Other continuous periodontal variables were 
not statistically significant in the model (mean CAL: F=0.06, p=0.81; percentage of sites 
with CAL≥4mm: F=0.74, p=0.39; number of missing teeth: F=0.15, p=0.70).  
 
The 3 different periodontitis definitions as were included individually included in the 
model. Chronic periodontitis as defined by DEF2 emerged as a statistically significant 
predictor of GFR deterioration, while DEF1 and DEF3 were not statistically significant 
(F=0.05, p=0.83; F=0.89, p=0.35, respectively). The direction of change predicted by 
chronic periodontitis DEF2 can be deduced by examining the estimated means of GFR 
in subjects with and without chronic periodontitis, shown in Table 17 (page 58). 
 
Twenty-two subjects had a needle-core biopsy report available. Information regarding 
the different time spans between the date of the transplant, date of biopsy, date of the 
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GFR measurements and the date of oral exam are shown in Table 18 (page 59). Most of 
the subjects had the biopsy taken within one year of the most recent GFR available. One 
subject, however, had the biopsy done more than 5 years before the date of the most 
recent GFR, which explains the skewed distribution and the large standard deviation 
observed. Based on the biopsy report, The BANFF CAN score was deduced for each 
subject. Percentage distribution of each score among the 22 subjects is shown in Figure 
1 (page 63). Due to the small sample size, the CAN score variable was dichotomized 
into a CAN group (Banff CAN scores 1, 2 and 3) vs. no CAN group (Banff CAN score 0). 
 
All 22 subjects that had a biopsy were from the GFR deterioration group. A student t-test 
was applied to examine if there were differences in the continuous periodontal variables 
(mean PD, mean CAL, percentage of sites with PD≥5mm, percentage of sites with 
CAL≥4mm, percentage sites BOP, number of missing teeth) among the two CAN score 
groups. There were no statistically significant differences among the two groups for any 
of the periodontal variables. A chi square test was used to examine any significant 
association between chronic periodontitis history (using the three different definitions) 
and the severity of CAN. No significant associations were found for all three definitions 
(according to DEF2, all but one subject had chronic periodontitis, which curtails 
statistical analysis). 
 
E. 
This secondary analysis of data was performed on a subset of the renal allograft 
recipient population reported in chapter (2). The subjects were included in the analysis if 
the available creatinine lab results were taken at least 6 months after the transplantation 
Discussion 
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and the two measurements were 6 months apart. Those cutoff points were chosen since 
one large study showed that allograft function at 6 months post-transplant, as 
measureby creatinine values, and the changes that occurred 6 months later were related 
to the 5-year survival of the graft.115 In our study, the GFR values were estimated using 
the simplified MDRD formula. The simplified MDRD formula showed comparable 
accuracy and correlation to other MDRD formulas in estimating GFR in renal transplant 
recipients, and better prediction of true GFR compared to the Cockcrof & Gault 
formula.116, 117
 
 
Conventionally, graft failure is suspected only when a continued and irreversible fall in 
renal function has become clinically apparent, generally, as a combination of 
hypertension and proteinuria. Subsequently, renal allograft biopsies are performed to 
identify acute graft dysfunction118. Recent studies have indicated that acute rejection 
episodes and CAN are often subclinical without any significant impairment of renal 
function119-121. These observations have sparked the debate regarding the validity and 
benefit of protocol/surveillence biopsies for stable renal allograft patients with the 
objective of early intervention in case of graft deterioration118
 
. 
The success that has been achieved in improving early survival rates of renal 
transplants is still over-shadowed by a significant drop in long-term patient and graft 
survival after 10 years.7 Several parameters have been shown to be correlated with 
long-term allograft outcomes such as acute rejection episodes,122 the number of human 
leukocyte antigen (HLA) mismatches,123 delayed graft function,124 and having a living vs. 
a cadaveric donor.125 Nevertheless, these parameters can’t explain the variation in the 
clinical course and outcome of organ transplantation. 
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A considerable body of research has focused on the role of genetic polymorphism in 
organ transplantation126-128. The primary hypothesis of such research is that genotypic 
differences lead to different phenotypes of immune responsiveness which is related to 
variable inflammatory cytokine, and other inflammatory molecule synthesis. Those 
differences are in turn determined by gene polymorphisms. Several cytokine gene 
polymorphisms have been examined, including INF-γ129-131, TNF-α131, 132, IL-10130 and IL-
6133, but associations with graft survival were not conclusive132 and often appeared 
contradictory130, 131, 133. Other mediator molecules investigated, with similar inconsistent 
findings, include growth factors, e.g. TGF-β130, 132, adhesion molecules (e.g. ICAM)134, 
and co-stimulatory molecules (e.g. CCR5)130, 135. Similarly, susceptibility to periodontitis 
has been hypothesized to be related to various gene polymorphisms. Researchers have 
investigated polymorphisms involving IL-196, 136, IL-698, TNF-α98, 137, vitamin D receptor138, 
TLR498, 139 and others140, but the associations with chronic or aggressive periodontitis 
were not consistent141, 142
 
. The inconsistent findings are possibly due to the complex 
inflammatory-mediator interactions, whereby a single nucleotide polymorphism is 
unlikely to explain the spectrum of variation observed in either or both CAN or 
periodontitis. Thus, our hypothesis is based on a broad assumption whereby a subjects’ 
“pro-inflammatory trait/phenotype” is inferred from periodontal disease experience, which 
in turn might predict worse long-term allograft outcomes. 
In this analysis, we proposed that history of periodontitis indicates a hyper-inflammatory 
phenotype, which could in turn cause greater susceptibility to renal allograft deterioration. 
This scheme of interaction does not necessarily assume causality, and could be 
extended to other areas where a link between periodontitis and various systemic 
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diseases is being investigated. In this analysis, periodontal destruction was measured 
using a series of continuous variables and 3 different “periodontitis case” definitions. The 
decision to include these 3 case definitions was triggered by a recent study113
 
 that 
showed that when different disease definitions were applied in the same patient 
population, considerably different associations were found when periodontitis and 
systemic diseases are investigated.  
Sixty percent of our patient cohort experienced a deterioration of GFR function by a 
median change of 48 mL/min/1.73m2, while 40% experienced a median improvement of 
44 mL/min/1.73m2. These numbers are generally in agreement with observations in 
other studies143, 144, with similar populations that compared renal function measures over 
time. At least 50% of the patient cohort had the two serum creatinine tests within 2.3 
years. The trend toward higher cytokine levels in the GFR improvement group might be 
considered counter-intuitive. Interestingly, Muller and colleagues found that a high-
expression IL-6 genotype was associated with better graft survival at 3 years. 145
 
 
Continuous periodontal variables were not statistically significantly different between the 
GFR groups. Clinically-small trends were, however, observed for greater periodontal 
destruction and inflammation in the GFR deterioration group as measured by the 
percentage of sites with BOP, mean PD and percentage of sites with PD≥5mm. When 
the 3 different definitions were used to classify the subjects into periodontally-healthy or -
diseased subjects, varying prevalence rates were observed. While periodontitis was 
more prevalent in the GFR deterioration group compared to the GFR improvement group 
according to the 3 definitions, the difference was statistically significant only when using 
DEF2. These findings underscore the importance of the “case definition of periodontitis” 
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in any study, especially studies investigating a link between periodontitis and systemic 
diseases. This is further highlighted by the fact that even when the differences between 
the criteria to define disease were small by clinical standards (DEF2 requires 6 proximal 
sites with PD≥5 or CAL ≥ 4 while DEF3 requires 8 sites), this was enough to have a 
bearing on the statistically significant associations found. 
 
In the multivariate analysis, the demographic and medical variables that were statistically 
significantly associated with GFR deterioration were history of acute rejection, having a 
living donor, and being hypertensive. Although history of acute rejection146, 147 and 
hypertension144
Table 19
 have been shown to be associated with allograft deterioration, renal 
allografts from living donors have higher survival rates compared to allografts from 
cadaveric donors (http://optn.transplant.hrsa.gov). Our finding of greater renal function 
deterioration in subjects with a renal transplant from a living donor could not be 
explained by examining the differences in the number of HLA mismatches, percentages 
of related and unrelated donors or number of episodes of acute rejection between 
transplant patients with a living vs. a cadaveric donor ( , Table 20 and Table 21; 
pages 60-62). Chronic periodontitis as defined by DEF2 was statistically significant in 
predicting GFR deterioration. Additionally, the continuous periodontal variables were 
introduced individually into the model, higher percentage of sites with BOP, higher mean 
PD and higher percentage of sites with PD≥5mm showed a trend towards statistical 
significance in predicting deterioration of allograft function (percentage sites BOP: 
F=3.27, p=0.08; mean PD: F=3.02, p=0.09; percentage of sites with PD≥5mm: F=2.28, 
p=0.14). These findings suggest that periodontal destruction might be a risk indicator for 
renal allograft deterioration. Although the analysis of the biopsy report did not yield any 
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significant findings, this might be due to the variation in the time period between the 
biopsy exam and the oral exam in this study, as well as the small sample size. 
    
Our analysis has several limitations. The GFR values are estimated from two creatinine 
measurements that were done at different time intervals for each patient. Also, the most 
recent serum creatinine measurement was not done at the same time of the oral 
examination. In addition, the single periodontal examination performed in this study does 
not permit accurate evaluation of the activity of the disease, although, our hypothesis 
addresses the existence of a susceptible phenotype as a risk indicator and not the 
causality of the link between active periodontitis and graft deterioration. Another 
limitation is that the timing of the biopsy was very variable in relation to the timing of the 
creatinine tests available (some biopsies were done before, between or after the 
creatinine lab tests). Finally, in the multivariate model, adjusting for medications 
introduced bias because patient records reveal that many subjects had frequent 
changes to their medication regimen. 
 
In conclusion, although our findings are suggestive of the potential for “periodontitis 
susceptibility” to predict renal allograft deterioration, no definitive conclusions can be 
drawn. Nevertheless, considering that this was a secondary analysis of cross-sectional 
data, and given the small sample size, this study could serve as a pilot study for power 
calculations in a future study. A longitudinal study design is necessary that would include 
subjects that receive an oral examination pre-transplantation, and whereby serial 
creatinine measurements, protocol biopsies and prospective monitoring of allograft 
function and periodontal status are conducted. Also, an intervention could be included in 
this design in which periodontitis patients would receive intensive periodontal treatment 
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pre- or post-transplant. These types of studies could not only support biologically 
plausible associations but also can demonstrate causality.
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IV. Concluding Remarks 
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1. Advanced periodontitis was found in 21% of the subjects in a population of stable 
renal and cardiac transplant patients. This was not statistically significantly 
different from prevalence in a control group (15%). 
2. Advanced periodontitis did not emerge as a statistically significant predictor of 
serum IL-6 or CRP in renal and cardiac transplant patients after adjusting for 
known modifiers of these cytokines. 
3. Serum IL-6 was moderately and positively correlated with gingival IL-6 mRNA 
expression, although this was a statistical trend only. 
4. Periodontal disease and periodontal inflammation, as measured by percentage of 
sites with BOP, mean PD and percentage of sites with PD≥5mm, indicated risk 
for renal allograft deterioration as measured from estimated GFR values (β=0.25, 
0.24, 0.22, respectively) . 
5. Periodontal parameters did not correlate with the chronic histologic changes 
observed in renal allograft biopsies. This analysis, however, involved only a small 
subset of the population. 
6. In studies evaluating the association between periodontitis and systemic 
diseases or conditions, the criteria used to define a periodontitis case have a 
significant influence on the resulting associations. 
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Table 1: Characteristics of transplant and control groups: 
Variable Transplant group 
(n=90) 
Control group (n=72) P value* 
Mean±
SD 
Median 
(quartiles) 
Mean±
SD 
Median 
(quartiles) 
Age (years) 53 ± 12  53.5 (44, 61) 51 ± 12 51 (43, 59) 0.33(NS) 
Gender (female) (%) 42%   60%   0.027 
Diabetics (%) 56%   3%   <0.001 
Smokers (current and 
former) (%) 
31%   0%   <0.001 
BMI 30.2 ± 
7.2 
29.3 (24.5, 
33.5) 
27.3 ± 
5.0 
26.2 (24.0, 
30.6) 
0.007 
PD (mm) 2.7 ± 
0.5 
2.6 (2.4, 3.0) 2.4 ± 
0.4 
2.4 (2.2, 2.7) 0.001 
CAL (mm) 2.9 ± 
0.7 
2.8 (2.5, 3.2) 2.7 ± 
0.6 
2.6 (2.3, 3.0) 0.06 
(NS) 
BOP (%) 17.0 ± 
16.7 
11.9 (4.8, 
22.5) 
22.0 ± 
16.7 
17.0 (8.7, 
34.0) 
0.06 
(NS) 
PI (%) 46.6 ± 
30.0 
45.9 (19.1, 
71.7) 
49.0 ± 
28.5 
53.3 (22.9, 
73.5) 
0.60 
(NS) 
No. of missing teeth  
** 
4.2 ± 
4.9 
3 (1, 6) 1.7 ± 
2.2 
1 (0, 3) <0.001 
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% Sites with CAL≥
4mm 
14.4 ±  
16.9 
8.7 (2.8, 
18.7) 
9.6 ± 
13.5 
3.8 (0.0, 
14.3) 
0.046 
% of sites with PD≥
5mm 
5.2 ± 
7.9 
1.3 (0.0, 8.3) 2.6 ± 
5.2 
0.0 (0.0, 2.6) 0.013 
Advanced  
periodontitis (%) 
21%  15%  0.34 
IL-6 (pg/ml) 5.0 ± 4.3 3.3 (2.4, 5.1) 3.0 ± 
1.6 
2.5 (2.0, 3.7)  <0.000 
CRP (mg/L) 0.9 ± 
1.63 
0.30 (0.10, 
0.82) 
0.28 ± 
0.39 
0.12 (0.05, 
0.28) 
<0.000 
 
SD: standard deviation, NS: not significant 
* t-test or chi square 
** 3rd molars excluded 
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Table 2: Medical and demographic data of the transplant population 
  Transplant subjects (n=90)* 
Transplant type (kidney) 90% 
Ethnicity (black) 32%  
Post-transplant years  6.9 ± 4.8, 5.0(3.0, 10.0) 
History of acute rejection 36% 
Pretransplant dialysis 68% 
Living donor (related or 
unrelated) 
42%  
Cyclosporin 24% 
Gingival overgrowth 6.0% 
Ca++ channel blockers 29% 
Prednisone 87% 
Mycophenolate 72% 
Tacrolimus 54% 
Azathioprine 10% 
Sirolimus 7% 
* Continuous variables shown as mean ± standard deviation, median (quartiles) and 
categorical variables reported as percentage frequency 
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Table 3: Multivariate linear regression analysis with serum IL-6 as the dependent 
variable 
Transplant 
group* 
Variable F p 
value 
β 
Age 7.93 <0.01 0.30 
Diabetes history 6.30 <0.02 0.27 
BMI 7.10 <0.01 0.29 
Cadaveric donor 6.21 <0.02 0.27 
Number of years post-transplant 3.00 0.09 0.19 
Number of missing teeth 3.52 0.06 0.21 
Control group** Variable F p value β 
Gender 0.002 0.96 <0.01 
Age 0.42 0.52 0.08 
Diabetes history 0.20 0.66 0.05 
BMI 3.56 0.06 0.24 
Advanced periodontitis 6.51 0.01 0.31 
percentage sites with BOP 10.40 <0.01 0.39 
* r2
** r
 = 0.30 
2 = 0.26 
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Table 4: Multivariate linear regression analysis in the transplant group with serum CRP 
as the dependent variable 
Transplant group* Variable F p value β 
Age 2.31 0.13 0.16 
Diabetes_Hx 8.48 0.005 0.30 
BMI 11.66 0.001 0.35 
Advanced periodontitis 1.56 0.22 0.14 
Control group* Variable F p value β 
Age 0.98 0.33 0.13 
Diabetes_Hx 0.81 0.37 0.11 
BMI 14.23 <0.001 0.43 
Advanced periodontitis 0.09 0.76 0.04 
* r2 = 0.23
** r
  
2 = 0.21 
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Table 5: Banff 97 Classification of Chronic Allograft Nephropathy in Biopsies 
 
Chronic Allograft Nephropathy 
Grade Histopathological findings 
1 (mild) Mild interstitial fibrosis and tubular atrophy without or with specific 
changes suggesting chronic rejection 
2 (moderate) Moderate interstitial fibrosis and tubular atrophy 
3 (severe) Severe interstitial fibrosis and tubular atrophy and tubular loss 
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Table 6: Demographic and Medical Characteristics 
 
Variable  Mean ± sd (frequency) Median  
Age  52.8±12.0 53.3 
Gender (female) (%) 41%  
Race (black) 24%  
Diabetics (%) 52%  
Smokers (current and former) 
(%) 
31%   
Yrs after transplant 7.6±4.9 (n=58) 7.1 (3.8, 11.0) 
History of acute rejection 33%  
Pre-transplant dialysis 78%  
Living donor (related or 
unrelated) 
43%  
 
Ca++ channel blockers 28%  
Cyclosporin 38%  
Prednisone 91%  
Mycophenolate 72%  
Tacrolimus 57%  
Azathioprine 21%  
Sirolimus 14%  
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Table 7: Estimated GFR Measurement Time Intervals and GFR Change: 
 
Variable Mean ± SD (frequency) Median (quartiles) 
Months between two GFR tests 44.7±43.1 Range (6-200) 
Median 28.5 
(13.8, 64.7) 
Months between oral exam and 
recent GFR 
26.7±24.4 Range (2-123) 
median 16.7 
(11.3, 34.2) 
GFR deterioration (% subjects) 60%  
GFR Deterioration (mL/min/1.73 
m2
56 
) 
48 (66, 36) 
GFR improvement (% subjects) 40%  
GFR Improvement (mL/min/1.73 
m2
44 
) 
44 (26, 56) 
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Table 8: Serum IL-6 and CRP cytokine levels in the GFR groups: 
 GFR improvement 
group (mean ± SD) 
GFR deterioration 
group (mean ± SD) 
p-value * 
IL-6 (pg/ml) 5.9 ± 2.0 4.1 ± 1.8 p=0.06 
CRP (mg/L) 0.92 ± 2.10  0.44 ± 1.50 p=0.11 
 
* Student t test
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Table 9: Continuous Periodontal Variables in the GFR Groups: 
 
Variable GFR deterioration GFR improvement P 
value* Mean±SD Median 
(25th, 75th
Mean±SD 
 
quartiles) 
Median (25th, 
75th
Mean PD (mm) 
 
quartiles) 
2.8 ± 0.4 2.7 (2.4, 
3.2) 
2.6 ± 0.5 2.6 (2.4, 3.0) 0.25 
(NS) 
Mean CAL (mm) 3.0 ± 0.8 2.8 (2.5, 
3.3) 
2.9 ± 0.7 2.7 (2.4, 3.4) 0.72 
(NS) 
BOP (% of sites) 18.8 ± 
15.5 
15.0 (6.5, 
25.0) 
14.7 ± 
13.8 
7.7 (4.6, 
28.5) 
0.14 
(NS) 
PI (% of sites) 50.7 ± 
29.0 
53.6 
(28.3, 
76.9) 
43.0 ± 
33.0 
42.4 (10.7, 
74.4) 
0.35 
(NS) 
No. of missing teeth ** 2.6 ± 2.6 2.0 (1.0, 
4.0) 
4.5 ± 4.5 4.0 (0.0, 8.0) 0.29 
(NS) 
Sites with CAL≥4mm (%) 16.6 ± 
20.1 
9.1 (3.1, 
19.2) 
14.9 ± 
19.8 
3.0 (1.8, 
20.8) 
0.30 
(NS) 
Sites with PD≥5mm (%) 7.0 ± 9.2 2.4 (0.0, 
12.3) 
5.6 ± 9.0 0.0 (0.0, 
11.4) 
0.22 
(NS) 
** excluding 3rd molars 
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Table 10: Prevalence of Chronic Periodontitis in the GFR Groups: 
 
Chronic periodontitis 
(prevalence in each group) 
GFR deterioration GFR improvement P value  
DEF 1 94% 87% p=0.44 * (NS) 
DEF 2 91% 70% p= 0.04 * 
DEF 3 57% 39% p=0.18 ** (NS) 
* Fisher’s exact test 
** Chi square test 
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Table 11: Serum IL-6 and CRP in periodontitis vs. non-periodontitis subjects (mean ± 
standard deviation) 
 
DEF1 
CP* No CP p value 
Serum IL-6 5.1 ± 1.9 4.6 ± 1.9 0.76 
Serum CRP 0.60 ± 1.8 0.45 ± 1.5 0.66 
 DEF2 
CP No CP p value 
Serum IL-6 4.7 ± 1.9 4.3 ± 1.7 0.70 
Serum CRP 0.68 ± 1.85 0.36 ± 1.34 0.11 
 DEF3 
CP No CP p value 
Serum IL-6 4.6 ± 1.8 4.7 ± 2.0 0.90 
Serum CRP 0.60 ± 1.7 0.60 ± 1.8 0.75 
 
* CP: chronic periodontitis 
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Table 12: Multivariate, repeated measures, linear regression* with GFR change over 
time as the dependent variable (statistically significant medical variables): 
 F p value 
GFR change over time (dependent variable) 6.23 .016 
 
Independent variables F p value β 
Partial eta 
squared 
Observed 
Power 
History of acute rejection 4.80 .033 0.30 0.09 0.58 
Living vs cadaveric donor 6.53 .014 0.34 0.12 0.71 
Hypertension 4.01 .051 0.28 0.08 0.50 
 
* n=53 
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Table 13: Estimated means of first (older) and second (recent) GFR within the 
categories of the significant variables: 
 
Variable  GFR (Mean ± SD*) (ml/min/1.73m2) 
No History of Acute rejection Time 1** 57.9 ± 34.6 
Time 2** 66.4 ± 33.7 
History of Acute rejection Time 1 84.5 ± 56.6 
Time 2 45.4 ± 25.8 
Cadaveric donor Time 1 53.7 ± 30.3 
Time 2 70.3 ± 36.8 
Living donor Time 1 88.8 ± 54.6 
Time 2 41.5 ± 21.6 
Non-hypertension Time 1 61.0 ± 38.1 
Time 2 66.2 ± 42.0 
Hypertension Time 1 81.5 ± 43.9 
Time 2 45.6 ± 27.1 
 
* SD: standard deviation 
** Time 1& Time 2: refers to the first and second serum creatinine measurement on 
record, respectively, regardless of whether it’s the highest or lowest value on record.  
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Table 14: Multivariate, repeated measures, linear regression with GFR change over time 
as the dependent variable (Including the statistically significant medical variables and 
individual continuous periodontal variables): 
 
 
 
Independent variables F 
P 
value 
β 
Partial Eta 
squared 
Observed Power 
History of acute rejection 4.80 .033 0.30 0.09 0.58 
Living vs cadaveric donor 6.53 .014 0.34 0.12 0.71 
Hypertension 4.01 .051 0.28 0.08 0.50 
      
Percentage of sites with BOP 3.27 0.08 0.25 0.06 0.43 
      
Mean PD 3.02 0.09 0.24 0.06 0.40 
      
Percentage of sites with 
PD≥5mm 
2.28 0.14 0.22 0.05 0.32 
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Table 15: Estimated means of first (older) and second (recent) GFR within the 
categories of each periodontal variable: percentage of sites with BOP, mean PD and 
percentage of sites with PD≥5mm: 
Variable  GFR (Mean ± SD*) (ml/min/1.73m2
Percentage of sites with BOP 
) 
(0% - <5%) Time 1** 69.6 ± 37.9 
Time 2** 67.8 ± 46.4 
(5% – 25%) Time 1 72.0 ± 47.2 
Time 2 45.5 ± 26.8 
(>25%) Time 1 67.1 ± 38.9 
Time 2 55.0 ± 20.3 
Percentage of sites with 
PD≥5mm 
(0%) Time 1 60.9 ± 35.0 
Time 2 60.2 ± 38.5 
(1 – 10%) Time 1 75.1 ± 54.6 
Time 2 47.1 ± 26.7 
(>10%) Time 1 77.1 ± 31.7 
Time 2 48.1 ± 24.8 
Mean PD (0.0 - 2.4)  Time 1 60.7 ± 38.8 
Time 2 64.2 ± 41.2 
(>2.4 - 3.1) Time 1 71.5 ± 50.4 
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Time 2 48.7 ± 29.4 
(>3.1)   Time 1 79.3 ± 32.2 
Time 2 45.8 ± 22.5 
 
* SD: standard deviation 
** Time 1& Time 2: refers to the first and second serum creatinine measurement on 
record, respectively, regardless of whether it’s the highest or lowest value on record.  
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Table 16: Multivariate, repeated measures, linear regression with GFR change over time 
as the dependent variable (including the statistically significant medical variables and 
chronic periodontitis DEF2): 
 
Independent variables F 
P 
value 
β 
Partial Eta 
squared 
Observed Power 
History of acute rejection 5.14 0.03 0.31 0.09 0.60 
Living vs cadaveric donor 7.00 0.01 0.36 0.12 0.74 
Hypertension 4.29 0.04 0.29 0.08 0.53 
Chronic periodontitis DEF2 4.51 0.04 0.29 0.08 0.55 
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Table 17: Estimated means of first (older) and second (recent) GFR within the 
categories of Periodontitis DEF2 variable: 
Variable  GFR (Mean ± SD*) (ml/min/1.73m2) 
Chronic periodontitis 
(DEF2) 
No periodontitis Time 1** 59.1 ± 24.9 
Time 2** 77.9 ± 48.4 
periodontitis Time 1 72.9 ± 44.7 
Time 2 46.8 ± 22.1 
 
* SD: standard deviation 
** Time 1& Time 2: refers to the first and second serum creatinine measurement on 
record, respectively, regardless of whether it’s the highest or lowest value on record.  
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Table 18: Renal Biopsy Time Variables: 
 
 Mean ±SD Median (quartiles) 
Time between transplant 
and biopsy (months) 
66.1 ± 55.0 52.2 (21.4, 95.0) 
Time between biopsy and 
most recent GFR (months) 
-2.22 ± 11.6 0.07 (-0.14, 0.20) 
Time between biopsy and 
oral exam (years) 
1.9 ± 1.4 1.3 (0.8, 2.9) 
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Table 19: Frequency distribution of cadaveric, living related and living unrelated donors 
 
Donor type Frequency Percentage 
Cadaveric 32 56% 
Living related 14 25% 
Living unrelated 11 19% 
Total 57 100% 
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Table 20: Cross-tabulation of donor type vs. history of acute rejection: 
Donor 
type  
History_of_acute_rejection 
Total 
0 1 
Cadaveric 
Frequency 
16 13 29 
Percentage within donor type 
group 
55.2% 44.8% 100.0% 
Percentage within history of 
acute rejection group 
45.7% 68.4% 53.7% 
Percentage of Total 
29.6% 24.1% 53.7% 
Living  
Frequency 
19 6 25 
Percentage with donor type 
group 
76.0% 24.0% 100.0% 
Percentage within history of 
acute rejection group 
54.3% 31.6% 46.3% 
Percentage of Total 
35.2% 11.1% 46.3% 
Count 
35 19 54 
Percentage within donor type group 
64.8% 35.2% 100.0% 
- Chi square (p=0.11) 
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Table 21: Cross-tabulation of donor type vs. number of HLA mismatches: 
Donor 
type  
Number of HLA mismatches 
Total 
Less than 3 3 or more 
Cadaveric 
Frequency 
2 19 21 
Percentage within donor type 
group 
9.5% 90.5% 100.0% 
Percentage within HLA 
mismatches group 
40.0% 59.4% 56.8% 
Percentage of Total 
5.4% 51.4% 56.8% 
Living  
Frequency 
3 13 16 
Percentage with donor type 
group 
18.8% 81.2% 100.0% 
Percentage within HLA 
mismatches group 
60.0% 40.6% 43.2% 
Percentage of Total 
8.1% 35.1% 43.2% 
Count 
35 5 32 
Percentage within donor type group 
64.8% 13.5% 86.5% 
 
- Fisher’s exact (p=0.42) 
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Figure 1: Percentage Distribution of CAN According to the Banff 97 Classification 
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